Vanda Pharmaceuticals Cash on Hand 2006-2019 | VNDA

Vanda Pharmaceuticals cash on hand from 2006 to 2019. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Vanda Pharmaceuticals Annual Cash on Hand
(Millions of US $)
2018 $257
2017 $143
2016 $141
2015 $143
2014 $130
2013 $131
2012 $121
2011 $149
2010 $198
2009 $205
2008 $46
2007 $85
2006 $32
2005 $31
Vanda Pharmaceuticals Quarterly Cash on Hand
(Millions of US $)
Q3 2019 $238
Q2 2019 $280
Q1 2019 $268
Q4 2018 $257
Q3 2018 $241
Q2 2018 $231
Q1 2018 $249
Q4 2017 $143
Q3 2017 $140
Q2 2017 $137
Q1 2017 $138
Q4 2016 $141
Q3 2016 $143
Q2 2016 $136
Q1 2016 $138
Q4 2015 $143
Q3 2015 $144
Q2 2015 $147
Q1 2015 $134
Q4 2014 $130
Q3 2014 $56
Q2 2014 $64
Q1 2014 $101
Q4 2013 $131
Q3 2013 $143
Q2 2013 $104
Q1 2013 $111
Q4 2012 $121
Q3 2012 $135
Q2 2012 $145
Q1 2012 $157
Q4 2011 $149
Q3 2011 $161
Q2 2011 $188
Q1 2011 $195
Q4 2010 $198
Q3 2010 $202
Q2 2010 $207
Q1 2010 $202
Q4 2009 $205
Q3 2009 $21
Q2 2009 $29
Q1 2009 $43
Q4 2008 $46
Q3 2008 $52
Q2 2008 $63
Q1 2008 $71
Q4 2007 $85
Q3 2007 $105
Q2 2007 $120
Q1 2007 $127
Q4 2006 $32
Q3 2006 $43
Q2 2006 $60
Q1 2006 $20
Q4 2005 $31
Q3 2005
Q2 2005
Q1 2005
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.826B $0.193B
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $129.829B 14.96
CSL (CSLLY) Australia $82.928B 0.00
Gilead Sciences (GILD) United States $80.729B 10.00
Celgene (CELG) United States $78.303B 11.18
Vertex Pharmaceuticals (VRTX) United States $52.716B 53.81
Biogen (BIIB) United States $49.649B 8.52
Illumina (ILMN) United States $43.871B 48.13
Regeneron Pharmaceuticals (REGN) United States $37.153B 16.27
Alexion Pharmaceuticals (ALXN) United States $23.432B 11.57
Seattle Genetics (SGEN) United States $19.416B 0.00
SINO PHARMACEUT (SBMFF) Hong Kong, SAR China $18.631B 0.00
Incyte (INCY) United States $18.479B 42.90
BioMarin Pharmaceutical (BMRN) United States $13.576B 0.00
Genmab (GNMSF) Denmark $13.448B 59.40
Bio-Rad Laboratories (BIO.B) United States $10.393B 49.88
Exact Sciences (EXAS) United States $10.288B 0.00
Alnylam Pharmaceuticals (ALNY) United States $10.085B 0.00
Galapagos (GLPG) Belgium $10.076B 25.96
BeiGene (BGNE) Cayman Islands $9.325B 0.00
QIAGEN (QGEN) Netherlands $8.407B 27.41
Bio-Techne Corp (TECH) United States $7.759B 51.93
Amarin (AMRN) Ireland $7.677B 0.00
Guardant Health (GH) United States $7.264B 0.00
Sarepta Therapeutics (SRPT) United States $7.261B 0.00
ACADIA Pharmaceuticals (ACAD) United States $7.004B 0.00
Reata Pharmaceuticals (RETA) United States $6.125B 0.00
Moderna (MRNA) United States $6.112B 0.00
Horizon Therapeutics Public (HZNP) Ireland $5.583B 14.19
ARGENX SE-ADR (ARGX) Netherlands $5.236B 0.00
Exelixis (EXEL) United States $5.062B 14.24
Ascendis Pharma (ASND) Denmark $4.702B 0.00
China Biologic Products (CBPO) China $4.594B 25.88
Spark Therapeutics (ONCE) United States $4.269B 0.00
Repligen (RGEN) United States $4.252B 77.06
Bluebird Bio (BLUE) United States $4.081B 0.00
Mirati Therapeutics (MRTX) United States $4.069B 0.00
Medicines (MDCO) United States $4.057B 0.00
Blueprint Medicines (BPMC) United States $3.547B 0.00
Adaptive Biotechnologies (ADPT) United States $3.393B 0.00
Immunomedics (IMMU) United States $3.345B 0.00
MorphoSys AG (MOR) Germany $3.294B 0.00
Alkermes (ALKS) Ireland $3.139B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $3.040B 0.00
Genmab (GMAB) Denmark $2.840B 5.85
Emergent Biosolutions (EBS) United States $2.806B 27.87
Intercept Pharmaceuticals (ICPT) United States $2.718B 0.00
Halozyme Therapeutics (HALO) United States $2.710B 0.00
NeoGenomics (NEO) United States $2.451B 130.44
MyoKardia (MYOK) United States $2.419B 0.00
Amicus Therapeutics (FOLD) United States $2.382B 0.00
UniQure (QURE) Netherlands $2.293B 0.00
Acceleron Pharma (XLRN) United States $2.282B 0.00
Arena Pharmaceuticals (ARNA) United States $2.276B 5.29
Zai Lab (ZLAB) China $2.262B 0.00
RA PHARMCTL INC (RARX) United States $2.197B 0.00
Ultragenyx Pharmaceutical (RARE) United States $2.125B 0.00
Cambrex (CBM) United States $2.019B 25.47
Ligand Pharmaceuticals (LGND) United States $1.841B 35.41
Myriad Genetics (MYGN) United States $1.823B 26.93
Akcea Therapeutics (AKCA) United States $1.794B 0.00
Insmed (INSM) United States $1.716B 0.00
Momenta Pharmaceuticals (MNTA) United States $1.588B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $1.460B 0.00
Denali Therapeutics (DNLI) United States $1.440B 0.00
Zymeworks (ZYME) Canada $1.417B 0.00
Epizyme (EPZM) United States $1.390B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.380B 0.00
REGENXBIO (RGNX) United States $1.337B 0.00
Coherus BioSciences (CHRS) United States $1.331B 0.00
Innoviva (INVA) United States $1.235B 3.64
Zealand Pharma (ZLDPF) Denmark $1.185B 0.00
Editas Medicine (EDIT) United States $1.163B 0.00
Sangamo Therapeutics (SGMO) United States $1.096B 0.00
Alector (ALEC) United States $1.069B 0.00
Fate Therapeutics (FATE) United States $1.067B 0.00
Zealand Pharma (ZEAL) Denmark $1.060B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.031B 0.00
Arvinas (ARVN) United States $1.014B 0.00
Principia Biopharma (PRNB) United States $1.004B 0.00
WAVE Life Sciences (WVE) Singapore $0.956B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.888B 0.00
Codexis (CDXS) United States $0.878B 0.00
Athenex (ATNX) United States $0.870B 0.00
Cara Therapeutics (CARA) United States $0.858B 0.00
Anika Therapeutics (ANIK) United States $0.853B 27.67
Vericel (VCEL) United States $0.829B 309.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.795B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.791B 0.00
Pharming Group (PHGUF) Netherlands $0.753B 0.00
Heska (HSKA) United States $0.711B 181.72
Twist Bioscience (TWST) United States $0.700B 0.00
Revance Therapeutics (RVNC) United States $0.685B 0.00
DBV Technologies S.A (DBVT) France $0.675B 0.00
ANI Pharmaceuticals (ANIP) United States $0.673B 11.47
Intellia Therapeutics (NTLA) United States $0.661B 0.00
MiMedx (MDXG) United States $0.650B 0.00
Mesoblast (MESO) Australia $0.600B 0.00
Precision BioSciences (DTIL) United States $0.599B 0.00
Adverum Biotechnologies (ADVM) United States $0.582B 0.00
Cellectis S.A (CLLS) France $0.581B 0.00
GENFIT S.A (GNFT) France $0.579B 0.00
BioDelivery Sciences (BDSI) United States $0.558B 0.00
Retrophin (RTRX) United States $0.555B 0.00
UROGEN PHARMA (URGN) United States $0.550B 0.00
Agenus (AGEN) United States $0.514B 0.00
Kadmon Holdings (KDMN) United States $0.508B 0.00
Dynavax Technologies (DVAX) United States $0.489B 0.00
Intra-Cellular Therapies (ITCI) United States $0.489B 0.00
Cytokineticsorporated (CYTK) United States $0.479B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.479B 0.00
Stemline Therapeutics (STML) United States $0.475B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.473B 0.00
AC Immune SA (ACIU) Switzerland $0.464B 10.73
Sinovac Biotech (SVA) China $0.460B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.448B 0.00
PHARMA MAR SA (PHMMF) Spain $0.432B 0.00
Prothena (PRTA) Ireland $0.427B 0.00
Merus (MRUS) Netherlands $0.374B 0.00
Arcus Biosciences (RCUS) United States $0.366B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.363B 2.51
Cellular Biomedicine (CBMG) United States $0.347B 0.00
Clovis Oncology (CLVS) United States $0.346B 0.00
Bellus Health (BLU) Canada $0.339B 0.00
PDL BioPharma (PDLI) United States $0.338B 8.46
AMAG Pharmaceuticals (AMAG) United States $0.334B 0.00
Starpharma Holdings (SPHRY) Australia $0.318B 0.00
Puma Biotechnology (PBYI) United States $0.312B 0.00
Kindred Biosciences (KIN) United States $0.305B 0.00
AnaptysBio (ANAB) United States $0.295B 0.00
Avid Bioservices (CDMO) United States $0.295B 0.00
Protagonist Therapeutics (PTGX) United States $0.294B 0.00
Compugen (CGEN) Israel $0.285B 0.00
Theratechnologies (THTX) Canada $0.279B 0.00
Geron (GERN) United States $0.274B 0.00
Seres Therapeutics (MCRB) United States $0.260B 0.00
Gritstone Oncology (GRTS) United States $0.256B 0.00
Sutro Biopharma (STRO) United States $0.250B 0.00
Biofrontera AG (BFRA) Germany $0.248B 370.00
CytomX Therapeutics (CTMX) United States $0.244B 0.00
MannKind (MNKD) United States $0.244B 0.00
Scholar Rock Holding (SRRK) United States $0.243B 0.00
ADMA Biologics Inc (ADMA) United States $0.240B 0.00
Kamada (KMDA) Israel $0.240B 7.01
Albireo Pharma (ALBO) United States $0.233B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.228B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.226B 0.00
Syros Pharmaceuticals (SYRS) United States $0.221B 0.00
Inovio Pharmaceuticals (INO) United States $0.220B 0.00
XOMA (XOMA) United States $0.218B 0.00
POXEL SA FRANCE (PXXLF) France $0.213B 0.00
Athersys (ATHX) United States $0.212B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.211B 0.00
Sorrento Therapeutics (SRNE) United States $0.211B 0.00
Exicure (XCUR) United States $0.208B 0.00
OSMOTICA PHARM (OSMT) United States $0.207B 0.00
Cue Biopharma (CUE) United States $0.207B 0.00
Spero Therapeutics (SPRO) United States $0.196B 0.00
Affimed (AFMD) Germany $0.185B 0.00
ChromaDex (CDXC) United States $0.184B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.183B 0.00
Bicycle Therapeutics (BCYC) United Kingdom $0.166B 0.00
Dyadic (DYAI) United States $0.163B 0.00
Senesco Technologies (ELOX) United States $0.162B 0.00
Arsanis (XFOR) United States $0.161B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.154B 0.00
Nicox SA (NICXF) France $0.150B 0.00
Alcobra (ARCT) United States $0.146B 0.00
Emmaus Life Sciences (EMMA) United States $0.135B 0.00
Cerecor (CERC) United States $0.133B 0.00
Five Prime Therapeutics (FPRX) United States $0.133B 0.00
Enzo Biochem (ENZ) United States $0.133B 0.00
Prometic Life Sciences (PFSCF) Canada $0.132B 0.00
Northwest Biotherapeutics (NWBO) United States $0.132B 0.00
Ophthotech (ISEE) United States $0.132B 0.00
Windtree Therapeutics (WINT) United States $0.129B 0.00
Mersana Therapeutics (MRSN) United States $0.126B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.123B 0.00
SESEN BIO, INC (SESN) United States $0.119B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.117B 0.00
Fortress Biotech (FBIO) United States $0.117B 0.00
Abeona Therapeutics (ABEO) United States $0.116B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.112B 0.00
Novavax (NVAX) United States $0.112B 0.00
NantKwest (NK) United States $0.110B 0.00
Aptinyx (APTX) United States $0.109B 0.00
Menlo Therapeutics (MNLO) United States $0.105B 0.00
OvaScience (MLND) United States $0.104B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.104B 0.00
VBI Vaccines (VBIV) United States $0.100B 0.00
PHASEBIO PHARMA (PHAS) United States $0.096B 0.00
Aduro Biotech (ADRO) United States $0.091B 0.00
Antibe Therapeutics (ATBPF) Canada $0.089B 0.00
Acorda Therapeutics (ACOR) United States $0.088B 0.00
Arbutus Biopharma (ABUS) Canada $0.087B 0.00
Celyad SA (CYAD) Belgium $0.086B 0.00
Adocia (ADOCY) France $0.086B 0.00
Strongbridge Biopharma (SBBP) United States $0.085B 2.26
VTv Therapeutics (VTVT) United States $0.084B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.084B 0.00
Aquinox Pharmaceuticals (NLTX) United States $0.079B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.078B 0.00
ARAVIVE, INC (ARAV) United States $0.075B 0.00
Synlogic (SYBX) United States $0.073B 0.00
Vaccinex (VCNX) United States $0.071B 0.00
Verastem (VSTM) United States $0.070B 0.00
Trevena (TRVN) United States $0.069B 0.00
Liquidia Technologies (LQDA) United States $0.067B 0.00
Prima BioMed (IMMP) Australia $0.067B 0.00
Selecta Biosciences (SELB) United States $0.067B 0.00
Checkpoint Therapeutics (CKPT) United States $0.066B 0.00
Catalyst Biosciences (CBIO) United States $0.064B 0.00
Idera Pharmaceuticals (IDRA) United States $0.062B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.062B 0.00
NewLink Genetics (NLNK) United States $0.060B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.057B 0.00
Proteostasis Therapeutics (PTI) United States $0.054B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.052B 0.00
Applied Genetic Technologies (AGTC) United States $0.052B 0.00
China Health Industries Holdings (CHHE) China $0.052B 15.78
Pluristem Therapeutics (PSTI) Israel $0.050B 0.00
Organovo Holdings (ONVO) United States $0.050B 0.00
Curis (CRIS) United States $0.048B 0.00
Orgenesis (ORGS) United States $0.048B 3.13
AquaBounty Technologies (AQB) United States $0.047B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.045B 0.00
Vascular Biogenics (VBLT) Israel $0.044B 0.00
Clearside Biomedical (CLSD) United States $0.044B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.044B 0.00
AIT Therapeutics (XAIR) United States $0.043B 0.00
DiaMedica Therapeutics (DMAC) United States $0.039B 0.00
Evogene (EVGN) Israel $0.037B 0.00
Celldex Therapeutics (CLDX) United States $0.037B 0.00
Stellar Biotechnologies (EDSA) Canada $0.036B 0.00
Oncobiologics (OTLK) United States $0.032B 0.00
Unum Therapeutics (UMRX) United States $0.031B 0.00
Celsion (CLSN) United States $0.031B 0.00
VIVUS (VVUS) United States $0.030B 0.00
INNOVATE BIOPHARMACEUTICALS, INC (INNT) United States $0.029B 0.00
Fibrocell Science Inc (FCSC) United States $0.029B 9.93
Caladrius Biosciences (CLBS) United States $0.029B 0.00
Bionano Genomics (BNGO) United States $0.029B 0.00
Entera Bio (ENTX) Israel $0.028B 0.00
Aptevo Therapeutics (APVO) United States $0.028B 0.00
BioCardia (BCDA) United States $0.026B 0.00
Alimera Sciences (ALIM) United States $0.023B 0.00
Signal Genetics (MGEN) United States $0.022B 0.00
Apricus Biosciences (SEEL) United States $0.021B 0.00
Aerpio Pharmaceuticals (ARPO) United States $0.021B 0.00
Aytu Bioscience (AYTU) United States $0.020B 0.00
AEterna Zentaris (AEZS) United States $0.020B 0.00
Soligenix (SNGX) United States $0.020B 0.00
Novogen (KZIA) Australia $0.020B 0.00
CollPlant Holdings (CLGN) Israel $0.017B 0.00
Pulmatrix (PULM) United States $0.015B 0.00
Prana Biotechnology (ATHE) Australia $0.015B 0.00
TOCAGEN INC (TOCA) United States $0.014B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.014B 0.00
MYOS RENS Technology (MYOS) United States $0.013B 0.00
VistaGen Therapeutics (VTGN) United States $0.013B 0.00
IMMURON (IMRN) Australia $0.013B 0.00
TrovaGene (TROV) United States $0.012B 0.00
Cesca Therapeutics (THMO) United States $0.011B 0.00
Titan Pharmaceuticals (TTNP) United States $0.011B 0.00
TRACON Pharmaceuticals (TCON) United States $0.010B 0.00
Benitec Biopharma (BNTC) Australia $0.008B 0.00
Genetic Technologies (GENE) Australia $0.008B 0.00
Advaxis (ADXS) United States $0.007B 0.00
Cleveland BioLabs (CBLI) United States $0.006B 0.00
Cyclacel Pharmaceuticals (CYCC) United States $0.006B 0.00
Neuralstem (SNCA) United States $0.002B 0.00